New Treatment on the Horizon
- In France, nearly 400,000 new cancer cases are diagnosed annually.
- Raphaël Rodriguez at the Institut Curie, in collaboration with the CNRS and Inserm, has developed a new class of therapeutic molecules, Fento-1 and Fento-2, designed to trigger ferroptosis,...
- oncologists are well aware of the challenges posed by metastatic cells.
French Researchers Target Metastatic Cancers with Novel Iron-Based therapy
Table of Contents
- French Researchers Target Metastatic Cancers with Novel Iron-Based therapy
- French Researchers Targeting Metastatic Cancers: Q&A
- what is the Main Focus of This Research?
- What are Metastatic Cancers and Why are They so Deadly?
- How Prevalent is Cancer in France?
- What Are the Challenges Presented by Metastatic Cancer Cells?
- What is ferroptosis and how Does it Work?
- Who is Leading This Research?
- What Are Fento-1 and Fento-2?
- What Results Were seen in Preclinical Models?
- What Kind of Cancer is Specifically Targeted by This Therapy?
- How Does This Treatment Differ from Customary Cancer Treatments?
- What is the Potential impact of This Research?
- What are the Next Steps?
- What is the Role of French Research in Advancing Cancer Treatments?
- What is Vectorized Internal Radiotherapy (RIV)?
- Can You Summarize the Key Aspects of This Research in a Table?
metastatic cancers“>In France, nearly 400,000 new cancer cases are diagnosed annually. Metastatic cancers, where cells spread to other organs, account for 90% of cancer-related deaths due to their resistance to standard treatments like chemotherapy and immunotherapy.
A team led by Dr. Raphaël Rodriguez at the Institut Curie, in collaboration with the CNRS and Inserm, has developed a new class of therapeutic molecules, Fento-1 and Fento-2, designed to trigger ferroptosis, a cell death mechanism targeting iron-rich cancer cells.
French Researchers Focus on Resistant Metastatic Cancers
Understanding Metastatic Cells
oncologists are well aware of the challenges posed by metastatic cells. Cancer cells from a primary tumor can migrate throughout the body,settling in areas like bones,liver,and brain,forming new,often more aggressive tumors. Current treatments often struggle against these secondary growths.
these metastatic cells exhibit resistance to conventional therapies, employing defense mechanisms and thriving on iron, an essential element that fuels their growth and survival against drug attacks.
Ferroptosis: Iron Overload as a Weapon
Dr. Rodriguez and his team recognized this iron dependence and designed molecules to induce ferroptosis, a targeted cell death process. The molecules force cancer cells to accumulate excessive iron, triggering an oxidation reaction that disintegrates the cell membrane, effectively causing the cell to “rust” from within and die.
Fento-1 and Fento-2 have shown promising results in preclinical models of metastatic breast cancer and in tissues from patients with pancreatic cancer and sarcomas, which are notoriously challenging to treat. These results include reduced tumor growth, targeted destruction of cancer cells, and minimal toxicity to healthy cells.
A Potential New Therapeutic Treatment?
Small Molecule, Important Therapeutic Potential
This development represents a potential paradigm shift in cancer therapy. Instead of attacking tumors indiscriminately, these molecules target a specific vulnerability of cancer cells, offering a more precise approach that could significantly improve outcomes for patients.
This discovery offers hope for treating resistant metastatic cancers,where current medical options are often limited. It may also have broader applications for other cancers that exhibit iron dependence.
Clinical Trials on the Horizon
While these laboratory and animal model results are encouraging, clinical trials on humans are necessary to evaluate the treatment’s safety and efficacy. If confirmed,these molecules could become part of the therapeutic arsenal in the coming years.
Researchers emphasize the potential of french biomedical research, highlighting the collaborative efforts of the CNRS, Inserm, the Institut Curie, and the Ministry of Research in advancing cancer treatments.
NOTEWORTHY
As October 2024, the Curie institute has offered vectorized internal radiotherapy (RIV) for metastatic prostate cancer patients. This technique involves injecting radioactive molecules that target cancer cells directly, irradiating the tumor from within while minimizing damage to healthy tissues.
French Researchers Targeting Metastatic Cancers: Q&A
what is the Main Focus of This Research?
This article discusses a new therapeutic approach developed by French researchers to combat metastatic cancers, which are cancers that have spread from their original site to other parts of the body. The research,led by Dr. Raphaël Rodriguez at the Institut Curie, focuses on novel molecules designed to trigger ferroptosis, a type of cell death that targets iron-rich cancer cells.
What are Metastatic Cancers and Why are They so Deadly?
Metastatic cancers are cancers that have spread from their origin site to other areas of the body. In France, they account for 90% of cancer-related deaths.This is because metastatic cells ofen become resistant to standard treatments like chemotherapy and immunotherapy, making them incredibly challenging to treat.
How Prevalent is Cancer in France?
In France, nearly 400,000 new cancer cases are diagnosed annually. In 2021, cancer claimed 162,400 lives in France: 90,900 men and 71,500 women.
What Are the Challenges Presented by Metastatic Cancer Cells?
Metastatic cancer cells are particularly challenging for several reasons:
- Spreading: They can migrate from the primary tumor to other parts of the body, forming new tumors in areas like the bones, liver, and brain.
- Resistance: They frequently enough develop resistance to conventional cancer therapies, such as chemotherapy and immunotherapy.
- Iron dependence: they thrive on iron, using it to fuel their growth and survival, making them difficult to eradicate with standard treatments.
What is ferroptosis and how Does it Work?
Ferroptosis is a type of programmed cell death that is triggered by the accumulation of excessive iron inside a cell.In this research, the molecules *Fento-1* and *Fento-2* are designed to induce this process:
- Iron Overload: These molecules force cancer cells to accumulate excessive amounts of iron.
- Oxidation and Cell Death: The excess iron triggers an oxidation reaction that damages and disintegrates the cell membrane, causing the cancer cell to “rust” from within and die.
Who is Leading This Research?
The research is led by Dr.Raphaël Rodriguez at the Institut Curie, in collaboration with the CNRS and Inserm.
What Are Fento-1 and Fento-2?
Fento-1 and Fento-2 are a new class of therapeutic molecules developed by the research team. They are designed to induce ferroptosis in cancer cells.
What Results Were seen in Preclinical Models?
The Fento-1 and Fento-2 molecules have shown promising results in preclinical models. These results, as mentioned in the text, include:
* Reduced tumor growth
* Targeted destruction of cancer cells
* Minimal toxicity to healthy cells
these results were observed in preclinical models of metastatic breast cancer and in tissues from patients with pancreatic cancer and sarcomas.
What Kind of Cancer is Specifically Targeted by This Therapy?
The therapy is being developed to target metastatic cancers, i.e. cancers that have spread from their original site to other parts of the body. In the preclinical trials, promising results were observed in metastatic breast cancer, pancreatic cancer, and sarcomas.
How Does This Treatment Differ from Customary Cancer Treatments?
Unlike some existing cancer treatments that might attack tumors indiscriminately, these molecules target a specific vulnerability of cancer cells, namely their iron dependence. This more precise approach may offer improved outcomes for patients by minimizing damage to healthy cells.
What is the Potential impact of This Research?
This research offers a potential paradigm shift in cancer therapy, particularly for resistant metastatic cancers where current treatment options are often limited. it could also have broader applications for other cancers that exhibit iron dependence.
What are the Next Steps?
Clinical trials on humans are necessary to evaluate the treatment’s safety and efficacy. If confirmed, these molecules could become part of the therapeutic arsenal in the coming years.
What is the Role of French Research in Advancing Cancer Treatments?
The researchers emphasize the collaborative efforts of French biomedical research, which involves the CNRS, Inserm, the Institut Curie, and the Ministry of Research, highlighting their combined potential in advancing cancer treatments.
What is Vectorized Internal Radiotherapy (RIV)?
In October 2024, The Curie Institute offered vectorized internal radiotherapy (RIV) for metastatic prostate cancer patients. This technique involves injecting radioactive molecules that target cancer cells directly, irradiating the tumor from within while minimizing damage to healthy tissues.
Can You Summarize the Key Aspects of This Research in a Table?
Certainly! Here’s a table summarizing the key aspects of the research:
| aspect | Details |
|---|---|
| Focus | Novel iron-based therapy for metastatic cancers. |
| Mechanism | Induces ferroptosis (iron-dependent cell death) in cancer cells. |
| Molecules | Fento-1 and Fento-2 |
| Target | Targets iron-rich cancer cells. |
| Preclinical Results | Reduced tumor growth, targeted cancer cell destruction, minimal toxicity to healthy cells. |
| Next Steps | Clinical trials on humans. |
| Potential | Paradigm shift in cancer therapy, especially for resistant metastatic cancers. |